abstract |
The present invention diagnoses and prognoses cancer, eg, early or late stage ovarian cancer, in a subject by detecting Bcl-2 in a biological sample, preferably a urine or blood sample obtained from the subject. And how to monitor. Bcl-2 can be measured using an agent that detects or binds to Bcl-2 protein or an agent that detects or binds to a coding nucleic acid, eg, an antibody that specifically reacts with Bcl-2 protein or a portion thereof. The invention further relates to a kit for carrying out the method of the invention. The invention further relates to an apparatus for rapid detection of Bcl-2 in body fluids and a method for rapidly measuring Bcl-2 in body fluids. |